Mga Batayang Estadistika
| LEI | 25490061CWK7F0OTY260 |
| CIK | 1809519 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GoodRx Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 6, 2025 |
Exhibit 99.1 GOODRX REPORTS SECOND QUARTER 2025 RESULTS Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year SANTA MONICA, Calif. - (August 6, 2025) - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has r |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 4, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2025 |
Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2025 RESULTS First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations SANTA MONICA, Calif. - (May 7, 2025) - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the |
|
| May 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 7, 2025 |
between GoodRx, Inc. and Pen Factory Property Owner, Exhibit 10.3 FIFTH AMENDMENT TO OFFICE LEASE This FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made and entered into as of January 2, 2025, by and between PEN FACTORY PROPERTY OWNER, LLC, a Delaware limited liability company (“Landlord”), and GOODRX, INC., a Delaware corporation (“Tenant”). R E C I T A L S : A.Landlord (as successor-in-interest to CSHV Pen Factory, LLC) and Tenant are part |
|
| April 23, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 27, 2025 |
Release, by and between GoodRx, Inc. 1 Exhibit 10.1 SEPARATION AGREEMENT & GENERAL RELEASE OF ALL CLAIMS This General Release of all Claims (this “Agreement”) is entered into by Karsten Voermann (the “Executive”) and GoodRx, Inc., a Delaware corporation (the “Corporation”), effective as of the Effective Date as defined herein. In consideration of the promises set forth herein, the Executive and the Corporation agree as follows: 1.Ter |
|
| February 27, 2025 |
List of Subsidiaries of GoodRx Exhibit 21.1 Legal Name Jurisdiction of Incorporation GoodRx Intermediate Holdings, LLC Delaware GoodRx, Inc. Delaware Iodine, Inc. Delaware GoodRx Care, LLC FKA HeyDoctor, LLC Delaware Lighthouse Acquisition Corp. Delaware Scriptcycle, LLC North Carolina HealthiNation Inc. Delaware RxSaver, Inc. Delaware Buckeye Acquisition, LLC DBA RxNXT Delaware flipMD, Inc. Delaware Pharmacy Services, LLC Dela |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 GoodRx Holdings, Inc. Insider Trading Compliance Policy I.Summary Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of GoodRx Holdings, Inc. (the “Company”) as well as that of all persons affiliated with the Company. Insider trading is a crime. The penalties for violating insider trading laws include imprisonment, disgo |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001- |
|
| February 27, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common sto |
|
| February 27, 2025 |
Exhibit 99.1 GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance SANTA MONICA, Calif. - (February 27, 2025) - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter |
|
| February 13, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 tm255901d6ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additio |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 5, 2025 |
between GoodRx, Inc. and Christopher Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of February 4, 2025, by and among GoodRx, Inc., a Delaware corporation (the “Corporation”), GoodRx Holdings, Inc. (“Holdings”) and Christopher McGinnis, an individual (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intention |
|
| January 24, 2025 |
EX-99.1 2 tm254251d1ex-1.htm EXHIBIT I EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Class A Common Stock, par value $0.0001 per share, of GoodRx Holdings, Inc. will be filed on behalf |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 21, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 7, 2025 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 16, 2024 |
Barnes, dated December 12, 2024 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of December 12, 2024, by and among GoodRx, Inc. |
|
| November 14, 2024 |
GDRX / GoodRx Holdings, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A 1 d876876dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 GoodRx Holdings, Inc (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 14, 2024 |
EX-99.I 2 d876876dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| November 14, 2024 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d876876dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated November 14, 2024 in connection with their beneficial ownership of GoodRx Holdings, Inc. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to whi |
|
| November 13, 2024 |
GDRX / GoodRx Holdings, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d8sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 38246G108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appr |
|
| November 7, 2024 |
Exhibit 99.1 GOODRX REPORTS THIRD QUARTER 2024 RESULTS SANTA MONICA, Calif. - (November 7, 2024) - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights •Revenue1 and Adjusted Revenue1 of $195.3 million •Net income of |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 28, 2024 |
Ronald E. Bruehlman Joins GoodRx Board of Directors Ronald E. Bruehlman Joins GoodRx Board of Directors IQVIA CFO brings 39 years of healthcare and finance expertise to GoodRx SANTA MONICA, Calif. October 28, 2024 - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the election of Ronald E. Bruehlman to its Board of Directors, effective Novembe |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 22, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 28, 2024 |
First Amendment to Second Amended and Restated Employment Agreement, by and between GoodRx, Inc. and Exhibit 10.1 FIRST AMENDMENT TO SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “First Amendment”), is made as of October 25, 2024 (the “Amendment Effective Date”), by and between GoodRx, Inc., (the “Corporation”) and Trevor Bezdek (the “Executive”). Capitalized terms used and not otherwise defined herein shall have th |
|
| October 10, 2024 |
GDRX / GoodRx Holdings, Inc. / BANK OF NOVA SCOTIA - BANK OF NOVA SCOTIA Passive Investment SC 13G/A 1 gdrxa1101024.htm BANK OF NOVA SCOTIA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GOODRX HOLDINGS INC (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| October 10, 2024 |
GDRX / GoodRx Holdings, Inc. / BANK OF NOVA SCOTIA - BANK OF NOVA SCOTIA Passive Investment SC 13G 1 gdrx101024.htm BANK OF NOVA SCOTIA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 GOODRX HOLDINGS INC (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| September 3, 2024 |
GDRX / GoodRx Holdings, Inc. / Spectrum Equity VII, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Carolina A. Picazo Spect |
|
| August 8, 2024 |
GOODRX REPORTS SECOND QUARTER 2024 RESULTS SANTA MONICA, Calif. - (August 8, 2024) - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights •Revenue1 and Adjusted Revenue1 of $200.6 million •Net income of $6.7 millio |
|
| August 8, 2024 |
Non-Employee Director Compensation Program, dated July GOODRX HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Amended and restated effective as of July 8, 2024 Eligible Directors (as defined below) on the board of directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non- Employee Director Compensation Program (this “Program”). The cash and equity compe |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 8, 2024 |
GOODRX HOLDINGS, INC. EXECUTIVE SEVERANCE PLAN Adopted on May 29, 2024 GoodRx Holdings, Inc., a Delaware corporation (the “Company”), has adopted this GoodRx Holdings, Inc. Executive Severance Plan, including the attached Exhibits (the “Plan”), for the benefit of Participants (as defined below) on the terms and conditions hereinafter stated. The Plan, as set forth herein, is intended to provide se |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 11, 2024 |
SIXTH AMENDMENT TO FIRST LIEN CREDIT AGREEMENT THIS SIXTH AMENDMENT TO FIRST LIEN CREDIT AGREEMENT, dated as of July 10, 2024 (this “Amendment”), by and among GOODRX, INC. |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 10, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 10, 2024 |
Ian T. Clark Joins GoodRx Board of Directors Ian T. Clark Joins GoodRx Board of Directors Former Genentech CEO brings over 35 years of pharmaceutical and healthcare expertise to GoodRx SANTA MONICA, Calif. July 10, 2024 - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the election of Ian T. Clark to its Board of Directors. Mr. Clark b |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 8, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 11, 2024 |
EX-7 3 formoftradingplanjb2024gr.htm EX-7 10b5-1 Preset Diversification Program® (PDP) 1 Table of Contents Part I.Account and Plan Information. Instructions: To be completed by MSSB and reviewed by the Seller. Part II.Trade Schedules. Trade Schedule A – Notice and Authorization of Exercise of Stock Options and Sale of Underlying Stock. Instructions: May not be applicable for some plans. For use by |
|
| June 11, 2024 |
GDRX / GoodRx Holdings, Inc. / GoodRx Holdings, Inc. - SC 13D/A Activist Investment SC 13D/A 1 gdrx-trevorbezdekschedule1.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Trevor Bezdek c/o GoodRx Holdings, Inc. 2701 Olympic Boulevard Santa Monica, CA 90404 |
|
| June 11, 2024 |
GDRX / GoodRx Holdings, Inc. / GoodRx Holdings, Inc. - SC 13D/A Activist Investment SC 13D/A 1 gdrx-douglashirschschedule.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Douglas Hirsch c/o GoodRx Holdings, Inc. 2701 Olympic Boulevard Santa Monica, CA 9040 |
|
| June 11, 2024 |
EX-7 3 formoftradingplanch2024gr.htm EX-7 10b5-1 Preset Diversification Program® (PDP) 1 Table of Contents Part I.Account and Plan Information. Instructions: To be completed by MSSB and reviewed by the Seller. Part II.Trade Schedules. Trade Schedule A – Notice and Authorization of Exercise of Stock Options and Sale of Underlying Stock. Instructions: May not be applicable for some plans. For use by |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 30, 2024 |
Simon Patterson Joins GoodRx Board of Directors Simon Patterson Joins GoodRx Board of Directors Former Dell Technologies and Skype Board member brings decades of tech, strategy and management experience to GoodRx SANTA MONICA, Calif. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 9, 2024 |
between GoodRx, Inc. and Pen Factory Property Owner, Exhibit 10.1 FOURTH AMENDMENT TO OFFICE LEASE This FOURTH AMENDMENT TO LEASE (this “Fourth Amendment”) is made and entered into as of February 7 , 2024, by and between PEN FACTORY PROPERTY OWNER, LLC, a Delaware limited liability company (“Landlord”), and GOODRX, INC., a Delaware corporation (“Tenant”). R E C I T A L S : A.Landlord (as successor-in-interest to CSHV Pen Factory, LLC) and Tenant are |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2024 |
GOODRX REPORTS FIRST QUARTER 2024 RESULTS Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2024 RESULTS SANTA MONICA, Calif. - (May 9, 2024) - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights •Revenue1 and Adjusted Revenue1 of $197.9 million •Net loss of |
|
| May 2, 2024 |
GDRX / GoodRx Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 GDRXSC13GMay2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 GOODRX HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 38246G108 (CUSIP Number) APRIL 25, 2024 (Date of event which requires filing of this statement) Check the appropriate box t |
|
| April 30, 2024 |
GoodRx Holdings, Inc. 2701 Olympic Boulevard Santa Monica, California 90404 April 30, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Matthew Crispino Re:GoodRx Holdings, Inc., Registration Statement on Form S-3 (Registration No. 333-278533) To the addressee set |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 5, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. |
|
| April 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) GoodRx Holdings, Inc. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 14, 2024 |
GoodRx Interim CEO Extends Commitment to Company Company Announces Board Resignations Exhibit 99.1 GoodRx Interim CEO Extends Commitment to Company Company Announces Board Resignations SANTA MONICA, Calif. – March 14, 2024 – GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx of their de |
|
| March 14, 2024 |
between GoodRx, Inc. and Scott Wagner, dated March 13, Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “First Amendment”), is made as of March 13, 2024 (the “Amendment Effective Date”), by and between GoodRx, Inc., a Delaware corporation (the “Corporation”) and Scott Wagner (“Executive”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the |
|
| March 8, 2024 |
GDRX / GoodRx Holdings, Inc. / Spectrum Equity VII, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Carolina A. Picazo Spect |
|
| March 8, 2024 |
GDRX / GoodRx Holdings, Inc. / FRANCISCO PARTNERS IV, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Steve Eisner Francisco P |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2024 |
between GoodRx, Inc. and Karsten Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of March 4, 2024 (the “Effective Date”) by and among GoodRx, Inc., a Delaware corporation (the “Corporation”) and Karsten Voermann, an individual (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions: A. The Executive c |
|
| February 29, 2024 |
Non-Employee Director Deferred Compensation Plan Exhibit 10.18 GOODRX HOLDINGS, INC. DEFERRED COMPENSATION PLAN FOR DIRECTORS Effective as of January 1, 2024 | TABLE OF CONTENTS Pages(s) ARTICLE I. DEFINITIONS 1 ARTICLE II. PURPOSE; DEFERRAL ELECTIONS 3 ARTICLE III. DEFERRED COMPENSATION ACCOUNTS 4 ARTICLE IV. PAYMENT OF DEFERRED COMPENSATION 5 ARTICLE V. ADMINISTRATION; EFFECTIVENESS, AMENDMENT AND TERMINATION OF PLAN 6 ARTICLE VI. MISCELLANEOU |
|
| February 29, 2024 |
GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2023 RESULTS Exhibit 99.1 GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2023 RESULTS SANTA MONICA, Calif. - (February 29, 2024) - GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on January 10, 2024 |
|
| February 29, 2024 |
GoodRx Holdings Inc. Policy for Exhibit 97.1 GOODRX HOLDINGS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION GoodRx Holdings, Inc. (the “Company”) believes that it is in the best interests of the Company and its equityholders to maintain a culture that emphasizes integrity and accountability. Therefore, the Company has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as |
|
| February 29, 2024 |
Form of Director Deferred RSU Agreement Exhibit 10.18.2 Director Deferred RSUs GOODRX HOLDINGS, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE GoodRx Holdings, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of |
|
| February 29, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common sto |
|
| February 29, 2024 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of GoodRx Holdings, Inc. (the “Company,” “we,” “us,” and “our”) and certain provisions of our amended and restated certificate of incorporation, as amended from time to time (the “amended and restated certificate of incorporation”) and amended and restated bylaws, as amended from time to time (the “amended and |
|
| February 29, 2024 |
Form of Director Deferred Cash Fees RSU Agreement Exhibit 10.18.1 Director Deferred Cash Fees GOODRX HOLDINGS, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE GoodRx Holdings, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and condition |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001- |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 29, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 29, 2024 |
List of Subsidiaries of GoodRx Holdings, Inc. Exhibit 21.1 Legal Name Jurisdiction of Incorporation GoodRx Intermediate Holdings, LLC Delaware GoodRx, Inc. Delaware Iodine, Inc. Delaware GoodRx Care, LLC FKA HeyDoctor, LLC Delaware Lighthouse Acquisition Corp. Delaware Scriptcycle, LLC North Carolina HealthiNation Inc. Delaware RxSaver, Inc. Delaware Buckeye Acquisition, LLC DBA RxNXT Delaware flipMD, Inc. Delaware Pharmacy Services, LLC Dela |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 26, 2024 |
GoodRx, Inc. and Raj Beri, dated February 22, 2024 Exhibit 10.2 SEPARATION AGREEMENT & RELEASE February 22, 2024 Raj Beri Dear Raj, As discussed, your last day of employment with GoodRx, Inc. (“GoodRx” or the “Company”) was February 15, 2024 (the “Separation Date”). This letter confirms the agreement (this “Agreement”) between you and the Company, on behalf of itself, its parent, subsidiaries, and other corporate affiliates, and each of their resp |
|
| February 26, 2024 |
Fifth Amendment to First Lien Credit Exhibit 10.1 EXECUTION VERSION FIFTH AMENDMENT TO FIRST LIEN CREDIT AGREEMENT THIS FIFTH AMENDMENT TO FIRST LIEN CREDIT AGREEMENT, dated as of February 20, 2024 (this “Amendment”), by and among GOODRX, INC., a Delaware corporation (the “Borrower”), GOODRX INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), the other Guarantors party hereto, BARCLAYS BANK PLC (“Barclays”) |
|
| February 14, 2024 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d931704dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2024 in connection with their beneficial ownership of GoodRx Holdings, Inc. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to whi |
|
| February 14, 2024 |
EX-99.I 2 d931704dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| February 14, 2024 |
GDRX / GoodRx Holdings, Inc. / AMERIPRISE FINANCIAL INC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 13, 2024 |
GDRX / GoodRx Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01032-goodrxholdingsinccla.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: GoodRx Holdings, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 38246G108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate |
|
| February 12, 2024 |
GDRX / GoodRx Holdings, Inc. / Rubric Capital Management LP - SC 13G Passive Investment SC 13G 1 tm245464d6sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 38246G108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate bo |
|
| January 25, 2024 |
GDRX / GoodRx Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 GDRXSC13GA2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) GOODRX HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 38246G108 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2024 |
Exhibit 99.1 GoodRx Announces Preliminary Fourth Quarter and Full Year 2023 Results and Early Expectations for First Quarter and Full Year 2024 Preliminary fourth quarter Revenue and Adjusted Revenue exceed previously announced guidance SANTA MONICA, Calif. - (January 10, 2024) - GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings, tod |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2024 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 22, 2023 |
Exhibit 99.1 GoodRx Appoints Kelly J. Kennedy to Board of Directors Former Chief Financial Officer of The Honest Company brings over 25 years of experience across retail and consumer brands SANTA MONICA, Calif. – December 22, 2023 – GoodRx (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced the election of Kelly J. Kennedy to its Board of Directors. Kennedy w |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 20, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 21, 2023 |
GDRX / GoodRx Holdings Inc - Class A / Spectrum Equity VII, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d555852dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Nu |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 9, 2023 |
GOODRX REPORTS THIRD QUARTER 2023 RESULTS Exhibit 99.1 GOODRX REPORTS THIRD QUARTER 2023 RESULTS SANTA MONICA, Calif. - (November 9, 2023) - GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, has released its financial results for the third quarter 2023. Third Quarter 2023 Highlights •Revenue1 of $180.0 million •Adjusted Revenue1,2 of $190.0 million •Net loss of $38 |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 27, 2023 |
Form of Trading Plan for Trevor Bezdek. EX-3 2 morganstanleyformof10b5-1t.htm EX-3 10b5-1 Preset Diversification Program® (PDP) 1 Table of Contents Part I. Account and Plan Information. Instructions: To be completed by MSSB and reviewed by the Seller. Part II. Trade Schedules. Trade Schedule A – Notice and Authorization of Exercise of Stock Options and Sale of Underlying Stock. Instructions: May not be applicable for some plans. For use |
|
| October 27, 2023 |
GDRX / GoodRx Holdings Inc - Class A / Bezdek Trevor - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Trevor Bezdek c/o GoodRx Holdings, Inc. 2701 Olympic Boulevard Santa Monica, CA 90404 (855) 268-2822 (Name, Address and Telephone Number |
|
| October 27, 2023 |
GDRX / GoodRx Holdings Inc - Class A / Hirsch Douglas Joseph - SC 13D/A Activist Investment SC 13D/A 1 gdrx-douglashirschschedule.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Douglas Hirsch c/o GoodRx Holdings, Inc. 2701 Olympic Boulevard Santa Monica, CA 9040 |
|
| October 27, 2023 |
Form of Trading Plan for Douglas Hirsch. EX-3 2 morganstanleyformof10b5-1t.htm EX-3 10b5-1 Preset Diversification Program® (PDP) 1 Table of Contents Part I. Account and Plan Information. Instructions: To be completed by MSSB and reviewed by the Seller. Part II. Trade Schedules. Trade Schedule A – Notice and Authorization of Exercise of Stock Options and Sale of Underlying Stock. Instructions: May not be applicable for some plans. For use |
|
| August 31, 2023 |
GDRX / GoodRx Holdings Inc - Class A / Hirsch Douglas Joseph - SC 13D Activist Investment SC 13D 1 gdrx-douglashirschschedule.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Douglas Hirsch c/o GoodRx Holdings, Inc. 2701 Olympic Boulevard Santa Monica, CA 90404 (855) |
|
| August 31, 2023 |
GDRX / GoodRx Holdings Inc - Class A / Bezdek Trevor - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Trevor Bezdek c/o GoodRx Holdings, Inc. 2701 Olympic Boulevard Santa Monica, CA 90404 (855) 268-2822 (Name, Address and Telephone Number of |
|
| August 9, 2023 |
Third Amendment to First Lien Credit Agreement, dated June 29, 2023 Exhibit 10.5 Executed Version THIRD AMENDMENT TO FIRST LIEN CREDIT AGREEMENT THIS THIRD AMENDMENT TO FIRST LIEN CREDIT AGREEMENT, dated as of June 29, 2023 (this “Amendment”), by and among GOODRX, INC., a Delaware corporation (the “Borrower”), each of the Revolving Lenders, and BARCLAYS BANK PLC (“Barclays”), as Administrative Agent (in such capacity, the “Administrative Agent”), amends that certa |
|
| August 9, 2023 |
Exhibit 99.1 GOODRX REPORTS SECOND QUARTER 2023 RESULTS Second quarter financial results exceed previously announced guidance SANTA MONICA, Calif. - (August 9, 2023) - GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, has released its financial results for the second quarter 2023. Second Quarter 2023 Highlights •Total reven |
|
| August 9, 2023 |
Fourth Amendment to First Lien Credit Agreement, dated July 7, 2023 Exhibit 10.6 Executed Version FOURTH AMENDMENT TO FIRST LIEN CREDIT AGREEMENT THIS FOURTH AMENDMENT TO FIRST LIEN CREDIT AGREEMENT, dated as of July 7, 2023 (this “Amendment”), by and among GOODRX, INC., a Delaware corporation (the “Borrower”), and BARCLAYS BANK PLC (“Barclays”), as Administrative Agent (in such capacity, the “Administrative Agent”), amends that certain First Lien Credit Agreement |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 27, 2023 |
Exhibit 10.1 SEPARATION AGREEMENT & RELEASE July 19, 2023 Babak Azad Dear Babak, As discussed, your last day of employment with GoodRx, Inc. (“GoodRx” or the “Company”) was July 7, 2023 (the “Separation Date”). This letter confirms the agreement (this “Agreement”) between you and the Company, on behalf of itself, its parent, subsidiaries, and other corporate affiliates, and each of their respectiv |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 GoodRx Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2023 GoodRx Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 2, 2023 |
Letter Agreement, by and between GoodRx, Inc. and Raj Beri, dated May 30, 2023 Exhibit 10.1 May 30, 2023 Raj Beri Dear Raj, Thank you for your continued service and dedication to GoodRx, Inc. (“GoodRx” or “the Company”) in your role as Chief Operating Officer. In recognition of your continued service and to incentivize your continued employment at GoodRx, GoodRx is pleased to offer you a retention bonus in the amount of $500,000, less all applicable withholdings and deductio |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 10, 2023 |
Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2023 RESULTS First quarter financial results exceed previously announced guidance SANTA MONICA, Calif. - (May 10, 2023) - GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading digital healthcare platform, has released its financial results for the first quarter 2023. First Quarter 2023 Highlights • Total revenue of $184.0 million, exc |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 25, 2023 |
EX-10.3 Exhibit 10.3 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 25, 2023 by and among GoodRx, Inc., a Delaware corporation (the “Corporation”) and Douglas Hirsch, an individual (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understan |
|
| April 25, 2023 |
Employment Agreement, by and between GoodRx, Inc. and Scott Wagner, dated April 25, 2023 EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 25, 2023 by and among GoodRx, Inc., a Delaware corporation (the “Corporation”) and Scott Wagner, an individual (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions: A. The Corporation and the Executive |
|
| April 25, 2023 |
EX-99.1 Exhibit 99.1 GoodRx Expands Executive Team With New Interim CEO Scott Wagner, Former CEO of GoDaddy, Appointed Interim CEO GoodRx Co-Founders Doug Hirsch and Trevor Bezdek to Serve as Chief Mission Officer and Chairman, Respectively SANTA MONICA, Calif., (April 25, 2023) – GoodRx Holdings, Inc. (NASDAQ: GDRX), a leading digital healthcare platform, today announced that Scott Wagner has bee |
|
| April 25, 2023 |
EX-10.2 Exhibit 10.2 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 25, 2023 by and among GoodRx, Inc., a Delaware corporation (the “Corporation”) and Trevor Bezdek, an individual (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understand |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2023 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 10, 2023 |
GDRX / GoodRx Holdings Inc - Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: GoodRx Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 38246G108 Date of Event Which Requires Filing of this Statement: February 28, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39549 GoodRx Holding |
|
| March 1, 2023 |
Offer Letter for Romin Nabiey, effective May 1, 2017 Exhibit 10.19 May 1, 2017 Romin Nabiey Re: GoodRx, Inc. Offer of Employment Dear Romin, On behalf of GoodRx, Inc., a Delaware corporation (the “Company”), we are pleased to offer you full-time employment in the position of Controller subject to the following terms and conditions. Start Date and Location Your employment start date will be on or before May 1, 2017. Your initial employment location w |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| March 1, 2023 |
List of Subsidiaries of GoodRx Holdings, Inc. Exhibit 21.1 Legal Name Jurisdiction of Incorporation GoodRx Intermediate Holdings, LLC Delaware GoodRx, Inc. Delaware Iodine, Inc. Delaware GoodRx Care, LLC FKA HeyDoctor, LLC Delaware Lighthouse Acquisition Corp. Delaware Scriptcycle, LLC North Carolina HealthiNation Inc. Delaware RxSaver, Inc. Delaware Buckeye Acquisition, LLC DBA RxNXT Delaware flipMD, Inc. Delaware Pharmacy Services, LLC Dela |
|
| March 1, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common sto |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 GoodRx Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 28, 2023 |
Exhibit 99.1 GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS Fourth quarter financial results exceed previously announced guidance SANTA MONICA, Calif. - (February 28, 2023) - GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading digital healthcare platform, has released its financial results for the fourth quarter and full year 2022. Fourth Quarter 2022 Highlights • Total revenue of $184.1 mil |
|
| February 9, 2023 |
GDRX / GoodRx Holdings, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0999-goodrxholdingsincclas.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: GoodRx Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 38246G108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate b |
|
| February 6, 2023 |
GDRX / GoodRx Holdings, Inc. Class A / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) GOODRX HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 38246G108 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designa |
|
| December 16, 2022 |
GDRX / GoodRx Holdings, Inc. Class A / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 GOODRX HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 38246G108 (CUSIP Number) DECEMBER 13, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 9, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39549 GoodRx Holdings, Inc. |
|
| November 8, 2022 |
Exhibit 99.1 GOODRX REPORTS THIRD QUARTER 2022 RESULTS Third quarter financial results exceed previously announced guidance SANTA MONICA, Calif. - (November 8, 2022) - GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital platform, has released its financial results for the third quarter of 2022. Third Quarter 2022 Highlights ? Total revenue of $187.3 million, exceeding previous |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 08, 2022 GoodRx Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 22, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 31, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 30, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 9, 2022 |
Exhibit 10.1 Date: May 6th, 2022 Name: Raj Beri Email: [email protected] Re: GoodRx, Inc. Offer of Employment Dear Raj, On behalf of GoodRx, Inc., a Delaware corporation (the ?Company? or ?GoodRx?), we are pleased to offer you full-time employment in the position of Chief Operating Officer, subject to the following terms and conditions (?Offer Letter?). Start Date and Location Your employment star |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39549 GoodRx Holdings, Inc. |
|
| August 8, 2022 |
Q2 2022 Letter to Shareholders August 8, 2022 Exhibit 99.2 Q2 2022 Letter to Shareholders August 8, 2022 GoodRx helps Americans get the healthcare they need at a price they can afford. Building the leading digital platform for consumer healthcare Unique combination of scale, Macro trends drive the First mover advantage and growth, and profitability1 need for our solutions and partnership strategy create a technology deep competitive moat Tran |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 8, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 8, 2022 |
GoodRx Releases Second Quarter 2022 Financial Results Exhibit 99.1 GoodRx Releases Second Quarter 2022 Financial Results SANTA MONICA, Calif. August 8, 2022 ? GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, has released its second quarter 2022 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will |
|
| June 28, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 GoodRx Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporat |
|
| June 28, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 14, 2022 (the ?Closing Date?), GoodRx Holdings, Inc. and its subsidiaries (collectively, ?GoodRx?) acquired all of the outstanding shares of capital stock of vitaCare Prescription Services, Inc. (?vitaCare?) from TherapeuticsMD, Inc. (the ?Seller?), the sole stockholder of vitaCare for an initial cash payment of $15 |
|
| June 28, 2022 |
vitaCare Prescription Services, Inc. Financial Statements As of and for the year ended December 31, 2021 INDEX TO FINANCIAL STATEMENTS Page Report of Independent Certified Public Accountants 2 Balance Sheet 4 Statement of Operations 5 Statement of Stockholder?s (Deficit) Equity 6 Statement of Cash Flows 7 Notes to Financial Statements 8 1 Report of Independent Certified Public Accountants Board of |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 18, 2022 |
May 18, 2022 Via EDGAR Attention: Inessa Kessman and Robert Littlepage United States Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39549 GoodRx Holdings, Inc. |
|
| May 10, 2022 |
Exhibit 10.2 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. Exhibit 10.2 Stock PURCHASE AGREEMENT By and between GOODRX, iNC., AND THERAPEUTICSMD, Inc. With respect to purchase of all the outstanding capital stock of VITACARE PRESCRIPTION SERVICES, INC. Dated as |
|
| May 10, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO OFFICE LEASE THIS THIRD AMENDMENT TO OFFICE LEASE dated effective as of January 1, 2022 (this ?Third Amendment?), is entered into by and between CSHV PEN FACTORY, LLC, a Delaware limited liability company (?Landlord?), and GOODRX, INC., a Delaware corporation (?Tenant?), with reference to the following: R E C I T A L S A. WHEREAS, Landlord and Tenant entered into th |
|
| May 9, 2022 |
Q1 2022 Letter to Shareholders May 9, 2022 Exhibit 99.2 Q1 2022 Letter to Shareholders May 9, 2022 GoodRx Holdings, Inc. Q1 2022 Letter to Shareholders 2 GoodRx helps Americans get the healthcare they need at a price they can afford. Our core values Advocate for equity We believe everyone should have access to high quality, affordable healthcare, no matter who they are or what their circumstances. Be accountable We hold ourselves and our c |
|
| May 9, 2022 |
Offer Letter for Raj Beri, dated May 6, 2022 Exhibit 10.1 Date: May 6th, 2022 Name: Raj Beri Email: [email protected] Re: GoodRx, Inc. Offer of Employment Dear Raj, On behalf of GoodRx, Inc., a Delaware corporation (the ?Company? or ?GoodRx?), we are pleased to offer you full-time employment in the position of Chief Operating Officer, subject to the following terms and conditions (?Offer Letter?). Start Date and Location Your employment star |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 3, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2022 |
GoodRx Releases First Quarter 2022 Financial Results Exhibit 99.1 GoodRx Releases First Quarter 2022 Financial Results SANTA MONICA, Calif. May 9, 2022 ? GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, has released its first quarter 2022 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will host |
|
| April 27, 2022 |
DEF 14A 1 d295822ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 20, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 25, 2022 |
April 25, 2022 Via EDGAR Attention: Inessa Kessman and Robert Littlepage United States Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N. |
|
| April 15, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 14, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 7, 2022 |
Exhibit 99.1 GoodRx Agrees to Acquire vitaCare, A Tech-Enabled Pharmacy Services Platform GoodRx expands offering to pharmaceutical manufacturers while helping to improve patient access and adherence to affordable brand drugs SANTA MONICA, Calif. March 7, 2022 ? GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it has entered into a definitive agreement |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 4, 2022 |
Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 38246G108 (CUSIP Number) March 2, 2022 Date of Event Which Requires Filing of this Statement Check the appropriate box |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| March 1, 2022 |
List of Subsidiaries of GoodRx Holdings, Inc. Exhibit 21.1 Legal Name Jurisdiction of Incorporation GoodRx Intermediate Holdings, LLC Delaware GoodRx, Inc. Delaware Iodine, Inc. Delaware GoodRx Care, LLC FKA HeyDoctor, LLC Delaware Lighthouse Acquisition Corp. Delaware Scriptcycle, LLC North Carolina HealthiNation Inc. Delaware RxSaver, Inc. Delaware Buckeye Acquisition, LLC DBA RxNXT Delaware |
|
| March 1, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common sto |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39549 GoodRx Holding |
|
| February 28, 2022 |
GoodRx Releases Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 GoodRx Releases Fourth Quarter and Full Year 2021 Financial Results SANTA MONICA, Calif. February 28, 2022 ? GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, has released its fourth quarter and full year 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goo |
|
| February 28, 2022 |
Exhibit 99.2 Exhibit 99.2 Q4 2021 Letter to Shareholders February 28, 2022 GoodRx helps Americans get the healthcare they need at a price they can afford. GoodRx helps my patients pay less for prescriptions and saves me time. It?s a better experience for all. Sharon Orrange, MD, MHS, FACP Internal Medicine The Doctors of USC Beverly Hills Dr. Orrange is a GoodRx advisor. GoodRx Holdings, Inc. Q4 2 |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2022 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2022 |
GDRX / GoodRx Holdings, Inc. Class A / Idea Men, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Trevor Bezdek c/o GoodRx Holdings, Inc., 2701 Olympic Boulevard Santa Monica, California 90404 (855) 268-2822 (Name, Address and Telephone |
|
| February 14, 2022 |
GDRX / GoodRx Holdings, Inc. Class A / Bezdek Family Irrevocable Trust - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of S |
|
| February 14, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of S |
|
| February 14, 2022 |
GDRX / GoodRx Holdings, Inc. Class A / Slutsky Andrew - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of S |
|
| February 10, 2022 |
GDRX / GoodRx Holdings, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: GoodRx Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 38246G108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 18, 2022 |
GDRX / GoodRx Holdings, Inc. Class A / Abdiel Qualified Master Fund LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 38246G108 (CUSIP Number) December 31, 2021 Date of Event Which Requires Filing of this Statement Check the appropriate box to |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39549 GoodRx Holdings, Inc. |
|
| November 10, 2021 |
GoodRx Releases Third Quarter 2021 Financial Results Exhibit 99.1 GoodRx Releases Third Quarter 2021 Financial Results SANTA MONICA, Calif. November 10, 2021 ? GoodRx Holdings, Inc. (Nasdaq: GDRX), America?s digital resource for healthcare, has released its third quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will host a conf |
|
| November 10, 2021 |
Exhibit 99.2 Q3 2021 Letter to Shareholders November 10, 2021 GoodRx helps Americans get the healthcare they need at a price they can afford. I use GoodRx myself because I have a high deductible insurance plan. Paying $100 for a medication is ridiculous even for a doctor. Alysia Ogburia, MD Primary Care Physician GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 2 Perspectives from Doug and Tre |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2021 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 5, 2021 |
GDRX / GoodRx Holdings, Inc. Class A / Idea Men, LLC - SC 13D/A Activist Investment SC 13D/A 1 d255899dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Trevor Bezdek c/o GoodRx Holdings, Inc., 2701 Olympic Boulevard Santa Monica, California 90404 (855 |
|
| August 31, 2021 |
CUSIP No. 38246G108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 38246G108 (CUSIP Number) August 30, 2021 Date of Event Which Requires Filing of this Statement Check the appropria |
|
| August 16, 2021 |
GDRX / GoodRx Holdings, Inc. Class A / Abdiel Qualified Master Fund LP - SC 13G Passive Investment SC 13G CUSIP No. 38246G108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 38246G108 (CUSIP Number) August 5, 2021 Date of Event Which Requires Filing of this Statement Check the appr |
|
| August 12, 2021 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. FIRST AMENDMENT TO OFFICE LEASE THIS FIRST AMENDMENT TO OFFICE LEASE (this ?First Amendment?), dated as of August 14, 2020 (the ?Effective Date?), is entered into by and between CSHV PEN FACTORY, LLC, a |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39549 GoodRx Holdings, Inc. |
|
| August 12, 2021 |
GoodRx Releases Second Quarter 2021 Financial Results Exhibit 99.1 GoodRx Releases Second Quarter 2021 Financial Results SANTA MONICA, Calif. August 12, 2021 ? GoodRx Holdings, Inc. (Nasdaq: GDRX), America?s leading resource for healthcare savings, has released its second quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will hos |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2021 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 12, 2021 |
Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| August 12, 2021 |
Exhibit 99.2 Q2 2021 Letter to Shareholders August 12, 2021 GoodRx Holdings, Inc. Q2 2021 Letter to Shareholders 2 GoodRx helps Americans get the healthcare they need at a price they can afford. GoodRx is giving patients access to medicines that they wouldn?t otherwise be able to afford. Joe Flores, MD Primary Care Physician Healthcare professionals represent about 17% of the people who visit Good |
|
| July 16, 2021 |
GDRX / GoodRx Holdings, Inc. Class A / Idea Men, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Trevor Bezdek c/o GoodRx Holdings, Inc., 2701 Olympic Boulevard Santa Monica, California 90404 (855) 268-2822 (Name, Address and Telephone |
|
| June 15, 2021 |
Submission of Matters to a Vote of Security Holders 8-K 1 d194567d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2021 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incor |
|
| June 1, 2021 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) Exhibit A JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned acknowledge and agree that the Statement on Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Class A Common Stock, par value $0. |
|
| June 1, 2021 |
GDRX / GoodRx Holdings, Inc. Class A / FRANCISCO PARTNERS IV, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Steve Eisner Francisco Partners One Letterman Drive, Building C - Suite 410 San Francisco, CA 94129 (415) 418-2900 (Name, Address and Telep |
|
| June 1, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| June 1, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). |
|
| June 1, 2021 |
GDRX / GoodRx Holdings, Inc. Class A / Silver Lake Group, L.L.C. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 38246G108 (CUSIP Number) Andrew J. Schader, Esq. Silver Lake 55 Hudson Yards 550 West 34th Street, 40th Floor New York, NY 10001 (212) |
|
| June 1, 2021 |
GDRX / GoodRx Holdings, Inc. Class A / Idea Men, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Trevor Bezdek c/o GoodRx Holdings, Inc., 2701 Olympic Boulevard Santa Monica, California 90404 (855) 268-2822 (Name, Address and Telephone |
|
| June 1, 2021 |
GDRX / GoodRx Holdings, Inc. Class A / Spectrum Equity VII, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 38246G108 (CUSIP Number) Carolina A. Picazo Spectrum Equity 140 New Montgomery St., 20th Floor, San Francisco, CA 94105 (415) 464-4600 (Name, Address and Telephone |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39549 GoodRx Holdings, Inc. |
|
| May 14, 2021 |
Form of Restricted Stock Unit Award pursuant to 2020 Incentive Award Plan Exhibit 10.2 GOODRX HOLDINGS, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice GoodRx Holdings, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the GoodRx Holdings, Inc. |
|
| May 14, 2021 |
First Amendment to 2020 Incentive Award Plan Exhibit 10.1 FIRST AMENDMENT TO GOODRX HOLDINGS, INC. 2020 INCENTIVE AWARD PLAN This First Amendment (?Amendment?) to the GoodRx Holdings, Inc. 2020 Incentive Award Plan (the ?Plan?), is adopted by the Board of Directors (the ?Board?) of GoodRx Holdings, Inc., a Delaware corporation (the ?Company?), as of April 1, 2021. Capitalized terms used in this Amendment and not otherwise defined herein shal |
|
| May 13, 2021 |
GoodRx Releases First Quarter 2021 Financial Results Exhibit 99.1 GoodRx Releases First Quarter 2021 Financial Results SANTA MONICA, Calif. May 13, 2021 ? GoodRx Holdings Inc. (Nasdaq: GDRX), America?s leading resource for healthcare savings, has released its first quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will host a co |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2021 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2021 |
Q1 2021 Letter to Shareholders May 13, 2021 Exhibit 99.2 Q1 2021 Letter to Shareholders May 13, 2021 GoodRx helps Americans get the healthcare they need at a price they can afford. I know with GoodRx, I?m going to be able to afford whatever my doctor prescribes Brenda S. GoodRx consumer GoodRx Holdings Inc. Q1 2021 Letter to Shareholders 2 Perspectives from Trevor and Doug Trust. In healthcare, trust is really, really hard to earn. America? |
|
| April 27, 2021 |
DEF 14A 1 gdrx-def14a20210610.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a‑101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: |
|
| April 27, 2021 |
DEFA14A 1 gdrx-defa14a20210610.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a‑101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 38246G108 (CUSIP Number) March 12, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| March 12, 2021 |
Offer Letter for Karsten Voermann, effective February 12, 2020 Exhibit 10.11 February 6, 2019 Karsten Voermann [email protected] Re: GoodRx, Inc. Offer of Employment Dear Karsten: On behalf of GoodRx, Inc., a Delaware corporation (the ?Company?), we are pleased to offer you full-time employment in the position of Chief Financial Officer subject to the following terms and conditions. Start Date and Location Your employment start date will be on or befo |
|
| March 12, 2021 |
List of Subsidiaries of GoodRx Holdings, Inc. Exhibit 21.1 Legal Name Jurisdiction of Incorporation GoodRx Intermediate Holdings, LLC Delaware GoodRx, Inc. Delaware Iodine, Inc. Delaware HeyDoctor, LLC Delaware Lighthouse Acquisition Corp. ScriptCycle, LLC Delaware North Carolina |
|
| March 12, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 12, 2021 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of GoodRx Holdings, Inc. (the ?Company,? ?we,? ?us,? and ?our?) and certain provisions of our amended and restated certificate of incorporation, as amended from time to time (the ?amended and restated certificate of incorporation?) and amended and restated bylaws, as amended from time to time (the ?amended and |
|
| March 12, 2021 |
Offer Letter for Bansi Nagji, dated March 28, 2020 Exhibit 10.10 March 28, 2020 Bansi Nagji [email protected] Re: GoodRx, Inc. Offer of Employment Dear Bansi: On behalf of GoodRx, Inc., a Delaware corporation (the ?Company?), we are pleased to offer you full-time employment in the position of President, Healthcare subject to the following terms and conditions. Start Date and Location Your employment start date will be as agreed upon between yo |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39549 GoodRx Holding |
|
| March 11, 2021 |
GoodRx helps Americans get the healthcare they need at a price they can afford. GoodRx Holdings, Inc. | Q4 2020 Letter to Shareholders page 2 GoodRx Holdings, Inc. | Q4 2020 Letter to Shareholders page 3 1 Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Refer to the |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2021 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 11, 2021 |
GoodRx Releases Fourth Quarter and Full Year 2020 Financial Results EX-99.1 Exhibit 99.1 GoodRx Releases Fourth Quarter and Full Year 2020 Financial Results SANTA MONICA, Calif. March 11, 2021 – GoodRx Holdings Inc. (Nasdaq: GDRX), America’s leading resource for healthcare savings, has released its fourth quarter and full year 2020 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.good |
|
| February 16, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Clas |
|
| February 16, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Se |
|
| February 16, 2021 |
SC 13G 1 tm216953d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 38246G108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GOODRX HOLDINGS, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 38246G108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 16, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Clas |
|
| February 12, 2021 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Titles of Class of Securities) 38246G108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 12, 2021 |
EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 12, 2021 |
EX-99.1 Exhibit 1 AGREEMENT OF JOINT FILING This joint filing agreement (this “Agreement”) is made and entered by and among SLP Geology Aggregator, L.P., SLP Geology GP, L.L.C., Silver Lake Technology Associates V, L.P., SLTA V (GP), L.L.C. and Silver Lake Group, L.L.C. The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filin |
|
| February 12, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Clas |
|
| February 12, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Clas |
|
| February 12, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* GoodRx Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Se |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: GoodRx Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 38246G108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1 |
|
| December 21, 2020 |
Unregistered Sales of Equity Securities - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2020 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 24, 2020 |
GDRX / GoodRx Holdings, Inc. Class A / LIGHT STREET CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GOODRX HOLDINGS, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 38246G108 (CUSIP Number) November 17, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| November 12, 2020 |
EX-99.2 Exhibit 99.2 FROM OUR CEOs Our mission has never been more relevant Hello. This is our first letter to you, our shareholders. Typically, shareholder letters aspire to project a stable, predictable world and profess a clear, easily achievable path for growth. But it’s 2020, and normal is out the window. We’re on the heels of a presidential election where healthcare policy became the single |
